Nathanael Gray

from Wikipedia, the free encyclopedia

Nathanael S. Gray is a biochemist and molecular biologist at Harvard Medical School and the Dana-Farber Cancer Institute .

Life

Gray grew up in Zambia , Yemen , India, and Sudan . He received a bachelor's degree from the University of California, Berkeley in 1995 and a Ph.D. in 1999 with Peter G. Schultz. in organic chemistry . At the Novartis Institute for Genomics (GNF) in San Diego , he headed the Biochemistry Department. Since 2006 he has been at Harvard Medical School, where he holds a professorship in biochemistry and molecular pharmacology, and at the Dana-Farber Cancer Institute, where he heads the department of chemical biology .

Gray is best known for his work on targeted cancer therapy by inactivating or breaking down cancer-promoting proteins , especially creatine kinases . To the (partly experimental) drugs that Gray and colleagues have developed include purvalanol , Ceritinib , Siponimod and ABL001 .

According to Google Scholar, Nathanael Gray has an h-index of 107, according to the Scopus database it is 93 (as of April 2020). He received the Eli Lilly Award in Biological Chemistry in 2011 and the Meyenburg Prize in 2013and the Paul Marks Prize for Cancer Research in 2019 .

Web links

Individual evidence

  1. ^ Nathanael S. Gray, PhD ( Memento from December 20, 2016 in the Internet Archive )
  2. ^ Nathanael Gray. In: scholar.google.de. Google Scholar , accessed April 17, 2020 .
  3. ^ Gray, Nathanael S. In: scopus.com. Scopus , accessed April 17, 2020 .
  4. ^ Eli Lilly Award. (PDF; 50 kB) In: divbiolchem.org. Division of Biological Chemistry of the American Chemical Society , accessed April 17, 2020 .
  5. Prize winners. In: meyenburg-stiftung.de. Meyenburg Foundation, accessed April 17, 2020 .
  6. ^ Paul Marks Prize for Cancer Research: 2019 Prize Winners. In: mskcc.org. Memorial Sloan Kettering Cancer Center , accessed April 17, 2020 .